Hydrafacial Investor Day Presentation Deck
Our three-year plan is expected to drive meaningful
profitable growth
2x net sales
vs. 2022E
54
3x+ Adj. EBITDA
vs. 2022E
$600 - $700mm 18 - 20%
2025E net sales
20-27% 2022E - 2025E CAGR¹
25-30%
2023E Adj. EBITDA margin 2025E Adj. EBITDA margin
Note: Adjusted EBITDA is a non-GAAP measure. See appendix for a definition and discussion. Our achievement of the anticipated results is subject to risks and uncertainties, including those disclosed in our filings
with the SEC. The plan does not take into account the impact of any unanticipated developments in the business or changes in the operating environment, nor does it take into account the impact of our
acquisitions, dispositions or financings during 2022. Our plan assumes a largely reopened global market, which would be negatively impacted if closures or other restrictive measures persist or are reimplemented;
1. Assuming midpoint of previously stated 2022 $340-350mm net sales guidance.
BEAUTYHEALTH™View entire presentation